{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-265867","form_type":"8-K","ticker":"LBRX","cik":"0001691082","company_name":"LB PHARMACEUTICALS INC","filed_at":"2026-06-10T20:16:40+00:00","discovered_at":"2026-06-10T20:18:00.352551+00:00","generated_at":"2026-06-10T20:26:48.495687+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"LB Pharmaceuticals CMO Anna Eramo resigns; will advise through September 15, 2026","bullets":["Anna Eramo, M.D., resigns as CMO effective June 15, 2026; transitions to advisor role through Sept 15, 2026.","Separation agreement includes base salary until June 15, 2027, prorated 2026 bonus, and accelerated vesting of 66,143 options.","Company states departure is unrelated to clinical operations and expects no material impact on clinical milestones.","Search for replacement underway; existing clinical teams will continue to oversee ongoing trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-265867","json":"https://secwatch.observer/filing/0001193125-26-265867.json","markdown":"https://secwatch.observer/filing/0001193125-26-265867.md","text":"https://secwatch.observer/filing/0001193125-26-265867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526265867/0001193125-26-265867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526265867/d221514d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T20:26:48.495687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"979b6ebc88","claim":"Anna Eramo resigned as Chief Medical Officer at LB PHARMACEUTICALS INC.","evidence_excerpt":"On June 8, 2026, she resigned from her position as Chief Medical Officer of the Company effective June 15, 2026 (the \" Separation Date \").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526265867/0001193125-26-265867-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}